{"id":"licensed-4cmenb-vaccine","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Injection site pain/erythema"},{"rate":"10-20","effect":"Fever"},{"rate":"20-30","effect":"Myalgia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant proteins from the meningococcal serogroup B capsule and outer membrane, which are presented to the immune system to generate both humoral (antibody) and cellular immune responses. This allows the body to recognize and neutralize the pathogen upon natural exposure, preventing invasive meningococcal disease caused by serogroup B strains.","oneSentence":"4CMenB is a recombinant meningococcal serogroup B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:05.304Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B"}]},"trialDetails":[{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT04084769","phase":"PHASE3","title":"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-03","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":570},{"nctId":"NCT02398396","phase":"NA","title":"Investigating Meningococcal Vaccines in Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-04","conditions":"Meningococcal Vaccines, Meningococcal Infections, Neisseria Meningitidis","enrollment":15},{"nctId":"NCT02569632","phase":"PHASE4","title":"Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2015-01","conditions":"Meningococcal Infections","enrollment":18},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03089086","phase":"PHASE4","title":"South Australian Meningococcal B Vaccine Herd Immunity Study","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2017-04-01","conditions":"Meningococcal Disease","enrollment":34489}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bexsero®"],"phase":"marketed","status":"active","brandName":"Licensed 4CMenB vaccine","genericName":"Licensed 4CMenB vaccine","companyName":"University of Adelaide","companyId":"university-of-adelaide","modality":"Biologic","firstApprovalDate":"","aiSummary":"4CMenB is a recombinant meningococcal serogroup B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}